Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Resch, U; Tatzber, F; Budinsky, A; Sinzinger, H.
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy.
Br J Clin Pharmacol. 2006; 61(3): 262-274.
Doi: 10.1111/j.1365-2125.2005.02568.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Tatzber Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To examine the effect of 24 weeks' rosuvastatin treatment on oxidative stress and changes in immune response to oxidized low-density lipoprotein (LDL). This was an open-label study of patients in Austria receiving 10 or 40 mg rosuvastatin daily alternately during 12 and 24 weeks. Circulating concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), both IgG and IgM type, to copper-oxidized LDL (Cu-OxLDL-IgG), concentrations of oxidized LDL complexed to IgG (OxLDL-IC) and markers of oxidative stress and systemic inflammation in subjects with plasma LDL cholesterol concentrations between 130 mg dl-1 and 250 mg dl-1 and triglycerides<or=400 mg dl-1 were determined. During statin therapy, plasma endogenous peroxides (POX-ACT) concentrations and peroxidase activity were significantly decreased, associated with a modest increase in total antioxidant capacity (TAC). Antibody titres to MDA-LDL-IgM, Cu-OxLDL-IgG and OxLDL-IC decreased, whereas MDA-LDL-IgG concentrations were increased after therapy. These changes were dose- and LDL-independent. POX-ACT concentrations were significantly positively correlated with inflammation markers before and after therapy and inversely with high-density lipoprotein-cholesterol concentrations after therapy. This study provides in vivo evidence that rosuvastatin significantly reduces oxidative stress and has immunomodulatory properties in a dose- and LDL-independent manner.
- Find related publications in this database (using NLM MeSH Indexing)
- Antioxidants - metabolism
- Autoantibodies - immunology
- Biomarkers - blood
- Copper - metabolism
- Dose-Response Relationship, Drug -
- Female -
- Fluorobenzenes - therapeutic use
- Humans -
- Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
- Immunoglobulin G - immunology
- Immunoglobulin M - immunology
- Lipoproteins, LDL - metabolism
- Male -
- Malondialdehyde - metabolism
- Middle Aged -
- Oxidation-Reduction -
- Oxidative Stress - drug effects
- Peroxidase - metabolism
- Peroxides - blood
- Pyrimidines - therapeutic use
- Rosuvastatin Calcium -
- Sulfonamides - therapeutic use
- Find related publications in this database (Keywords)
- autoantibodies
- oxidative stress
- oxidatively modified low-density lipoprotein
- rosuvastatin